

Vaibhav G Patel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8140831/publications.pdf>

Version: 2024-02-01

32
papers

1,587
citations

932766

10
h-index

610482

24
g-index

33
all docs

33
docs citations

33
times ranked

2668
citing authors

#	ARTICLE	IF	CITATIONS
1	Bone-modifying agents for bone loss in patients with prostate cancer receiving androgen deprivation therapy; insights from a network meta-analysis. Supportive Care in Cancer, 2022, 30, 855-863.	1.0	2
2	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 388-396.	2.0	15
3	Clinical utility of next-generation sequencing for prostate cancer in the context of a changing treatment landscape.. Journal of Clinical Oncology, 2022, 40, 112-112.	0.8	1
4	Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).. Journal of Clinical Oncology, 2022, 40, 138-138.	0.8	0
5	DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.. Journal of Clinical Oncology, 2022, 40, 129-129.	0.8	0
6	The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer. JNCI Cancer Spectrum, 2022, 6, .	1.4	6
7	The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer.. Journal of Clinical Oncology, 2021, 39, 41-41.	0.8	5
8	Prostate Cancer Dormancy and Reactivation in Bone Marrow. Journal of Clinical Medicine, 2021, 10, 2648.	1.0	11
9	Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate. Supportive Care in Cancer, 2021, 30, 981.	1.0	2
10	The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic. Frontiers in Oncology, 2021, 11, 734963.	1.3	4
11	Treatment of muscle-invasive and advanced bladder cancer in 2020. Ca-A Cancer Journal for Clinicians, 2020, 70, 404-423.	157.7	507
12	Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients. Cancer Medicine, 2020, 9, 8571-8578.	1.3	43
13	CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. JCO Precision Oncology, 2020, 4, 382-392.	1.5	51
14	Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors. Expert Review of Anticancer Therapy, 2020, 20, 503-512.	1.1	11
15	Smoking status and immunotherapy outcomes in smoking-associated cancers.. Journal of Clinical Oncology, 2020, 38, e15097-e15097.	0.8	1
16	What happens at radiographic disease progression in patients with metastatic cancer receiving immune checkpoint inhibitors? A single institution analysis.. Journal of Clinical Oncology, 2020, 38, e15157-e15157.	0.8	0
17	Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors.. Journal of Clinical Oncology, 2020, 38, e15160-e15160.	0.8	3
18	Type, timing, and risk factors associated with immune-related adverse event development in patients with advanced genitourinary cancers treated with immune checkpoint inhibitor.. Journal of Clinical Oncology, 2020, 38, 480-480.	0.8	2

#	ARTICLE	IF	CITATIONS
19	The evolving landscape of immunotherapy in advanced prostate cancer. <i>Immunotherapy</i> , 2019, 11, 903-912.	1.0	22
20	The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. , 2019, 7, 278.		586
21	Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2019, 76, 782-789.	0.9	38
22	Atezolizumab in "Real World" Patients: Do Phase 3b Trials Help Bridge the Gap Between Efficacy and Effectiveness?. <i>European Urology</i> , 2019, 76, 82-83.	0.9	0
23	Effect of concurrent beta-blocker (BB) use in patients receiving immune checkpoint inhibitors for metastatic urothelial (mUC) and renal cell carcinomas (mRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 467-467.	0.8	5
24	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. <i>European Urology</i> , 2018, 73, 751-759.	0.9	99
25	Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience. <i>Supportive Care in Cancer</i> , 2018, 26, 197-202.	1.0	8
26	The role of ketoconazole in current prostate cancer care. <i>Nature Reviews Urology</i> , 2018, 15, 643-651.	1.9	48
27	Survival after Metastasectomy for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. <i>Bladder Cancer</i> , 2017, 3, 121-132.	0.2	30
28	DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 300-300.	0.8	7
29	Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. <i>European Urology</i> , 2016, 70, 771-775.	0.9	69
30	Prognostic significance of DNA damage repair (DDR) mutations in patients with urothelial carcinoma (UC) and associations with tumor infiltrating lymphocytes (TILs).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4538-4538.	0.8	6
31	Prognostic significance of PIK3CA mutation in patients with muscle-invasive urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e16002-e16002.	0.8	0
32	Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1259-1265.	1.1	5